Skip to content

AbbVie

NYSE: ABBV · USD

AbbVie financials

6 charts

Revenue

USD millions

$16,990M
AbbVie Revenue. Quarterly values and changes versus the preceding comparable period. Missing values are unavailable.
PeriodRevenue
FY 2013 Q1$4,329M; Change unavailable vs FY 2012 Q4
FY 2013 Q2$4,692M; +8.4% vs FY 2013 Q1
FY 2013 Q3$4,658M; −0.7% vs FY 2013 Q2
FY 2013 Q4$5,111M; +9.7% vs FY 2013 Q3
FY 2014 Q1$4,563M; −10.7% vs FY 2013 Q4
FY 2014 Q2$4,926M; +8.0% vs FY 2014 Q1
FY 2014 Q3$5,019M; +1.9% vs FY 2014 Q2
FY 2014 Q4$5,452M; +8.6% vs FY 2014 Q3
FY 2015 Q1$5,040M; −7.6% vs FY 2014 Q4
FY 2015 Q2$5,475M; +8.6% vs FY 2015 Q1
FY 2015 Q3$5,944M; +8.6% vs FY 2015 Q2
FY 2015 Q4$6,400M; +7.7% vs FY 2015 Q3
FY 2016 Q1$5,958M; −6.9% vs FY 2015 Q4
FY 2016 Q2$6,452M; +8.3% vs FY 2016 Q1
FY 2016 Q3$6,432M; −0.3% vs FY 2016 Q2
FY 2016 Q4$6,796M; +5.7% vs FY 2016 Q3
FY 2017 Q1$6,538M; −3.8% vs FY 2016 Q4
FY 2017 Q2$6,944M; +6.2% vs FY 2017 Q1
FY 2017 Q3$6,995M; +0.7% vs FY 2017 Q2
FY 2017 Q4$7,739M; +10.6% vs FY 2017 Q3
FY 2018 Q1$7,934M; +2.5% vs FY 2017 Q4
FY 2018 Q2$8,278M; +4.3% vs FY 2018 Q1
FY 2018 Q3$8,236M; −0.5% vs FY 2018 Q2
FY 2018 Q4$8,305M; +0.8% vs FY 2018 Q3
FY 2019 Q1$7,828M; −5.7% vs FY 2018 Q4
FY 2019 Q2$8,255M; +5.5% vs FY 2019 Q1
FY 2019 Q3$8,479M; +2.7% vs FY 2019 Q2
FY 2019 Q4$8,704M; +2.7% vs FY 2019 Q3
FY 2020 Q1$8,619M; −1.0% vs FY 2019 Q4
FY 2020 Q2$10,425M; +21.0% vs FY 2020 Q1
FY 2020 Q3$12,902M; +23.8% vs FY 2020 Q2
FY 2020 Q4$13,858M; +7.4% vs FY 2020 Q3
FY 2021 Q1$13,010M; −6.1% vs FY 2020 Q4
FY 2021 Q2$13,959M; +7.3% vs FY 2021 Q1
FY 2021 Q3$14,342M; +2.7% vs FY 2021 Q2
FY 2021 Q4$14,886M; +3.8% vs FY 2021 Q3
FY 2022 Q1$13,538M; −9.1% vs FY 2021 Q4
FY 2022 Q2$14,583M; +7.7% vs FY 2022 Q1
FY 2022 Q3$14,812M; +1.6% vs FY 2022 Q2
FY 2022 Q4$15,121M; +2.1% vs FY 2022 Q3
FY 2023 Q1$12,225M; −19.2% vs FY 2022 Q4
FY 2023 Q2$13,865M; +13.4% vs FY 2023 Q1
FY 2023 Q3$13,927M; +0.4% vs FY 2023 Q2
FY 2023 Q4$14,301M; +2.7% vs FY 2023 Q3
FY 2024 Q1$12,310M; −13.9% vs FY 2023 Q4
FY 2024 Q2$14,462M; +17.5% vs FY 2024 Q1
FY 2024 Q3$14,460M; 0.0% vs FY 2024 Q2
FY 2024 Q4$15,102M; +4.4% vs FY 2024 Q3
FY 2025 Q1$13,343M; −11.6% vs FY 2024 Q4
FY 2025 Q2$15,423M; +15.6% vs FY 2025 Q1
FY 2025 Q3$15,776M; +2.3% vs FY 2025 Q2
FY 2025 Q4$16,618M; +5.3% vs FY 2025 Q3
FY 2026 Q1$15,002M; −9.7% vs FY 2025 Q4
FY 2026 Q2$16,990M; +13.3% vs FY 2026 Q1
Mar 31, 2013 through Sep 25, 2026

Free cash flow

USD millions

$3,114M
AbbVie Free cash flow. Quarterly values and changes versus the preceding comparable period. Missing values are unavailable.
PeriodFree cash flow
FY 2013 Q1$1,099M; Change unavailable vs FY 2012 Q4
FY 2013 Q2$1,918M; +74.5% vs FY 2013 Q1
FY 2013 Q3$1,665M; −13.2% vs FY 2013 Q2
FY 2013 Q4$1,094M; −34.3% vs FY 2013 Q3
FY 2014 Q1$487M; −55.5% vs FY 2013 Q4
FY 2014 Q2$1,575M; +223.4% vs FY 2014 Q1
FY 2014 Q3$1,606M; +2.0% vs FY 2014 Q2
FY 2014 Q4$-731M; −145.5% vs FY 2014 Q3
FY 2015 Q1$1,440M; +297.0% vs FY 2014 Q4
FY 2015 Q2$1,717M; +19.2% vs FY 2015 Q1
FY 2015 Q3$2,028M; +18.1% vs FY 2015 Q2
FY 2015 Q4$1,818M; −10.4% vs FY 2015 Q3
FY 2016 Q1$2,007M; +10.4% vs FY 2015 Q4
FY 2016 Q2$1,787M; −11.0% vs FY 2016 Q1
FY 2016 Q3$1,341M; −25.0% vs FY 2016 Q2
FY 2016 Q4Unavailable; Change unavailable vs FY 2016 Q3
FY 2017 Q1$2,007M; Change unavailable vs FY 2016 Q4
FY 2017 Q2$1,877M; −6.5% vs FY 2017 Q1
FY 2017 Q3$3,145M; +67.6% vs FY 2017 Q2
FY 2017 Q4$2,402M; −23.6% vs FY 2017 Q3
FY 2018 Q1$2,526M; +5.2% vs FY 2017 Q4
FY 2018 Q2$2,752M; +8.9% vs FY 2018 Q1
FY 2018 Q3$4,242M; +54.1% vs FY 2018 Q2
FY 2018 Q4$3,269M; −22.9% vs FY 2018 Q3
FY 2019 Q1$2,910M; −11.0% vs FY 2018 Q4
FY 2019 Q2$2,349M; −19.3% vs FY 2019 Q1
FY 2019 Q3$4,401M; +87.4% vs FY 2019 Q2
FY 2019 Q4$3,112M; −29.3% vs FY 2019 Q3
FY 2020 Q1$3,690M; +18.6% vs FY 2019 Q4
FY 2020 Q2$2,912M; −21.1% vs FY 2020 Q1
FY 2020 Q3$5,613M; +92.8% vs FY 2020 Q2
FY 2020 Q4$4,575M; −18.5% vs FY 2020 Q3
FY 2021 Q1$4,689M; +2.5% vs FY 2020 Q4
FY 2021 Q2$4,695M; +0.1% vs FY 2021 Q1
FY 2021 Q3$7,718M; +64.4% vs FY 2021 Q2
FY 2021 Q4$4,888M; −36.7% vs FY 2021 Q3
FY 2022 Q1$4,746M; −2.9% vs FY 2021 Q4
FY 2022 Q2$4,862M; +2.4% vs FY 2022 Q1
FY 2022 Q3$7,425M; +52.7% vs FY 2022 Q2
FY 2022 Q4$7,215M; −2.8% vs FY 2022 Q3
FY 2023 Q1$4,018M; −44.3% vs FY 2022 Q4
FY 2023 Q2$6,141M; +52.8% vs FY 2023 Q1
FY 2023 Q3$7,355M; +19.8% vs FY 2023 Q2
FY 2023 Q4$4,548M; −38.2% vs FY 2023 Q3
FY 2024 Q1$3,847M; −15.4% vs FY 2023 Q4
FY 2024 Q2$2,030M; −47.2% vs FY 2024 Q1
FY 2024 Q3$5,198M; +156.1% vs FY 2024 Q2
FY 2024 Q4$6,757M; +30.0% vs FY 2024 Q3
FY 2025 Q1$1,400M; −79.3% vs FY 2024 Q4
FY 2025 Q2$4,884M; +248.9% vs FY 2025 Q1
FY 2025 Q3$6,643M; +36.0% vs FY 2025 Q2
FY 2025 Q4$4,889M; −26.4% vs FY 2025 Q3
FY 2026 Q1$3,564M; −27.1% vs FY 2025 Q4
FY 2026 Q2$3,114M; −12.6% vs FY 2026 Q1

Net margin

%

21.27%
AbbVie Net margin. Reported fiscal history.
Fiscal period%
FY 2013 Q1—
FY 2013 Q2—
FY 2013 Q3—
FY 2013 Q4—
FY 2014 Q1—
FY 2014 Q2—
FY 2014 Q3—
FY 2014 Q4—
FY 2015 Q120.28%
FY 2015 Q224.95%
FY 2015 Q320.84%
FY 2015 Q423.7%
FY 2016 Q122.73%
FY 2016 Q224.95%
FY 2016 Q324.84%
FY 2016 Q420.47%
FY 2017 Q126.17%
FY 2017 Q227.58%
FY 2017 Q323.32%
FY 2017 Q40.67%
FY 2018 Q135.08%
FY 2018 Q223.96%
FY 2018 Q333.35%
FY 2018 Q4-21.99%
FY 2019 Q131.37%
FY 2019 Q28.98%
FY 2019 Q322.22%
FY 2019 Q432.18%
FY 2020 Q134.92%
FY 2020 Q2-7.08%
FY 2020 Q317.89%
FY 2020 Q40.26%
FY 2021 Q127.31%
FY 2021 Q25.49%
FY 2021 Q322.17%
FY 2021 Q427.17%
FY 2022 Q133.17%
FY 2022 Q26.34%
FY 2022 Q326.66%
FY 2022 Q416.35%
FY 2023 Q11.96%
FY 2023 Q214.6%
FY 2023 Q312.77%
FY 2023 Q45.75%
FY 2024 Q111.12%
FY 2024 Q29.47%
FY 2024 Q310.8%
FY 2024 Q4-0.15%
FY 2025 Q19.64%
FY 2025 Q26.08%
FY 2025 Q31.18%
FY 2025 Q410.93%
FY 2026 Q14.63%
FY 2026 Q221.27%

P/E

× · TTM · Daily

74.57×
AbbVie P/E. Monthly closing observations; inspect daily values with the chart arrow keys.
Close date× · TTM · DailyFinancials through
2014-02-2819.86×2013-12-31
2014-03-3120.05×2013-12-31
2014-04-3020.31×2013-12-31
2014-05-3021.12×2014-03-31
2014-06-3021.94×2014-03-31
2014-07-3120.34×2014-03-31
2014-08-2921.32×2014-06-30
2014-09-3022.27×2014-06-30
2014-10-3124.47×2014-06-30
2014-11-2830.01×2014-09-30
2014-12-3128.38×2014-09-30
2015-01-3026.18×2014-09-30
2015-02-2755.01×2014-12-31
2015-03-3153.23×2014-12-31
2015-04-3058.79×2014-12-31
2015-05-2958.96×2015-03-31
2015-06-3059.49×2015-03-31
2015-07-3161.99×2015-03-31
2015-08-3148.9×2015-06-30
2015-09-3042.64×2015-06-30
2015-10-3046.66×2015-06-30
2015-11-3034.35×2015-09-30
2015-12-3134.99×2015-09-30
2016-01-2932.43×2015-09-30
2016-02-2917.44×2015-12-31
2016-03-3118.24×2015-12-31
2016-04-2919.48×2015-12-31
2016-05-3118.67×2016-03-31
2016-06-3018.37×2016-03-31
2016-07-2919.65×2016-03-31
2016-08-3118.29×2016-06-30
2016-09-3017.99×2016-06-30
2016-10-3115.91×2016-06-30
2016-11-3017.35×2016-06-30
2016-12-3017.87×2016-06-30
2017-01-3117.44×2016-06-30
2017-02-2816.97×2016-12-31
2017-03-3117.88×2016-12-31
2017-04-2818.09×2016-12-31
2017-05-3118.11×2016-12-31
2017-06-3019.89×2016-12-31
2017-07-3119.18×2016-12-31
2017-08-3118.29×2017-06-30
2017-09-2921.58×2017-06-30
2017-10-3121.92×2017-06-30
2017-11-3023.46×2017-09-30
2017-12-2923.41×2017-09-30
2018-01-3127.17×2017-09-30
2018-02-2835.21×2017-12-31
2018-03-2928.77×2017-12-31
2018-04-3029.35×2017-12-31
2018-05-3130.08×2017-12-31
2018-06-2928.16×2017-12-31
2018-07-3128.04×2017-12-31
2018-08-3129.18×2017-12-31
2018-09-2828.75×2017-12-31
2018-10-3123.67×2017-12-31
2018-11-3028.66×2017-12-31
2018-12-3128.02×2017-12-31
2019-01-3124.41×2017-12-31
2019-02-2821.03×2018-12-31
2019-03-2921.39×2018-12-31
2019-04-3021.07×2018-12-31
2019-05-3120.36×2018-12-31
2019-06-2819.3×2018-12-31
2019-07-3117.68×2018-12-31
2019-08-3017.45×2018-12-31
2019-09-3020.1×2018-12-31
2019-10-3121.11×2018-12-31
2019-11-2923.29×2018-12-31
2019-12-3123.5×2018-12-31
2020-01-3121.5×2018-12-31
2020-02-2816.25×2019-12-31
2020-03-3114.45×2019-12-31
2020-04-3015.59×2019-12-31
2020-05-2916.36×2020-03-31
2020-06-3017.34×2020-03-31
2020-07-3116.76×2020-03-31
2020-08-3122.81×2020-06-30
2020-09-3020.86×2020-06-30
2020-10-3020.27×2020-06-30
2020-11-3025.3×2020-09-30
2020-12-3125.93×2020-09-30
2021-01-2924.8×2020-09-30
2021-02-2642.1×2020-12-31
2021-03-3142.29×2020-12-31
2021-04-3043.57×2020-12-31
2021-05-2844.23×2020-12-31
2021-06-3044.01×2020-12-31
2021-07-3045.44×2020-12-31
2021-08-3147.19×2020-12-31
2021-09-3042.15×2020-12-31
2021-10-2944.81×2020-12-31
2021-11-3027.42×2021-09-30
2021-12-3132.2×2021-09-30
2022-01-3132.56×2021-09-30
2022-02-2822.94×2021-12-31
2022-03-3125.16×2021-12-31
2022-04-2922.8×2021-12-31
2022-05-3121.1×2022-03-31
2022-06-3021.93×2022-03-31
2022-07-2920.55×2022-03-31
2022-08-3118.98×2022-06-30
2022-09-3018.94×2022-06-30
2022-10-3120.66×2022-06-30
2022-11-3021.43×2022-09-30
2022-12-3021.49×2022-09-30
2023-01-3119.65×2022-09-30
2023-02-2823.26×2022-12-31
2023-03-3124.09×2022-12-31
2023-04-2822.84×2022-12-31
2023-05-3132.47×2023-03-31
2023-06-3031.71×2023-03-31
2023-07-3135.21×2023-03-31
2023-08-3130.11×2023-06-30
2023-09-2930.54×2023-06-30
2023-10-3128.92×2023-06-30
2023-11-3038.91×2023-09-30
2023-12-2942.35×2023-09-30
2024-01-3144.92×2023-09-30
2024-02-2964.87×2023-12-31
2024-03-2867.1×2023-12-31
2024-04-3059.93×2023-12-31
2024-05-3147.96×2024-03-31
2024-06-2851.02×2024-03-31
2024-07-3155.12×2024-03-31
2024-08-3065.5×2024-06-30
2024-09-3065.89×2024-06-30
2024-10-3168.02×2024-06-30
2024-11-2963.66×2024-09-30
2024-12-3161.84×2024-09-30
2025-01-3164×2024-09-30
2025-02-2872.74×2024-09-30
2025-03-3172.91×2024-09-30
2025-04-3067.89×2024-09-30
2025-05-3079.18×2025-03-31
2025-06-3078.97×2025-03-31
2025-07-3180.42×2025-03-31
2025-08-2999.82×2025-06-30
2025-09-30109.85×2025-06-30
2025-10-31103.44×2025-06-30
2025-11-28171.11×2025-09-30
2025-12-31171.71×2025-09-30
2026-01-30167.59×2025-09-30
2026-02-2798.46×2025-12-31
2026-03-3192.27×2025-12-31
2026-04-3089.66×2025-12-31
2026-05-29107.14×2026-03-31
2026-06-30123.83×2026-03-31
2026-07-31123.49×2026-03-31
2026-08-3172.34×2026-06-30
2026-09-2574.57×2026-06-30
Mean 39.76×Median 27.37×172% above median

ROIC

% · Annual / TTM

20.04%
AbbVie ROIC. Reported fiscal history.
Fiscal period% · Annual / TTM
FY 2013 Q1—
FY 2013 Q2—
FY 2013 Q3—
FY 2013 Q4—
FY 2014 Q139.99%
FY 2014 Q243.25%
FY 2014 Q338.88%
FY 2014 Q428.34%
FY 2015 Q127.86%
FY 2015 Q215.58%
FY 2015 Q319.4%
FY 2015 Q432.76%
FY 2016 Q133.57%
FY 2016 Q220.06%
FY 2016 Q321.78%
FY 2016 Q422.28%
FY 2017 Q122.16%
FY 2017 Q220.67%
FY 2017 Q321.5%
FY 2017 Q418.95%
FY 2018 Q122.07%
FY 2018 Q224.04%
FY 2018 Q327.94%
FY 2018 Q4—
FY 2019 Q1—
FY 2019 Q2—
FY 2019 Q3—
FY 2019 Q456.22%
FY 2020 Q159.44%
FY 2020 Q216.98%
FY 2020 Q318.78%
FY 2020 Q4—
FY 2021 Q1—
FY 2021 Q2—
FY 2021 Q3—
FY 2021 Q418.42%
FY 2022 Q119.02%
FY 2022 Q218.91%
FY 2022 Q320.6%
FY 2022 Q420.72%
FY 2023 Q117.86%
FY 2023 Q220.05%
FY 2023 Q318.4%
FY 2023 Q415.5%
FY 2024 Q115.37%
FY 2024 Q214.35%
FY 2024 Q315.23%
FY 2024 Q4—
FY 2025 Q1—
FY 2025 Q2—
FY 2025 Q3—
FY 2025 Q415.6%
FY 2026 Q115.19%
FY 2026 Q220.04%

Capital allocation

% of tracked cash uses

$3,401M
AbbVie capital allocation. Quarterly values. Missing values are unavailable.
PeriodCapexAcquisitionsBuybacksDividendsDebt repaymentsTracked uses
FY 2013 Q110.72% · $88M0% · $0M11.81% · $97M77.47% · $636MUnavailable100% · $821M
FY 2013 Q213.01% · $119M14.64% · $134M2.62% · $24M69.73% · $638MUnavailable100% · $915M
FY 2013 Q313.34% · $133M22.47% · $224MUnavailable64.19% · $640MUnavailable100% · $997M
FY 2013 Q414.52% · $151M4.52% · $47M19.33% · $201M61.63% · $641MUnavailable100% · $1,040M
FY 2014 Q112.38% · $137MUnavailable29.72% · $329M57.9% · $641MUnavailable100% · $1,107M
FY 2014 Q216.92% · $142MUnavailable2.86% · $24M80.21% · $673MUnavailable100% · $839M
FY 2014 Q312.78% · $180M39.42% · $555MUnavailable47.8% · $673MUnavailable100% · $1,408M
FY 2014 Q413% · $153M4.25% · $50M25.49% · $300M57.26% · $674MUnavailable100% · $1,177M
FY 2015 Q17.22% · $145M36.64% · $736M17.02% · $342M39.12% · $786MUnavailable100% · $2,009M
FY 2015 Q20.69% · $115M64.43% · $10,752M29.98% · $5,002M4.9% · $818MUnavailable100% · $16,687M
FY 2015 Q36.43% · $127M0% · $0M50.53% · $998M43.04% · $850MUnavailable100% · $1,975M
FY 2015 Q46.56% · $145M0% · $0M55.43% · $1,225M38.01% · $840MUnavailable100% · $2,210M
FY 2016 Q18.16% · $121M1.89% · $28M27.6% · $409M62.35% · $924MUnavailable100% · $1,482M
FY 2016 Q21.8% · $131M33.3% · $2,427M52.18% · $3,803M12.72% · $927MUnavailable100% · $7,288M
FY 2016 Q310.58% · $113M2.06% · $22MUnavailable87.36% · $933MUnavailable100% · $1,068M
FY 2016 Q43.95% · $114M0.62% · $18M63.14% · $1,824M32.29% · $933MUnavailable100% · $2,889M
FY 2017 Q14.71% · $95MUnavailable44.37% · $895M50.92% · $1,027MUnavailable100% · $2,017M
FY 2017 Q210.91% · $126MUnavailable0.43% · $5M88.66% · $1,024MUnavailable100% · $1,155M
FY 2017 Q310.89% · $126M0% · $0M0.43% · $5M88.68% · $1,026MUnavailable100% · $1,157M
FY 2017 Q410.6% · $182M0% · $0M29.41% · $505M59.99% · $1,030MUnavailable100% · $1,717M
FY 2018 Q14.43% · $119MUnavailable53.26% · $1,431M42.31% · $1,137MUnavailable100% · $2,687M
FY 2018 Q21.24% · $114MUnavailable82.04% · $7,516M16.71% · $1,531MUnavailable100% · $9,161M
FY 2018 Q310.25% · $282MUnavailable36.66% · $1,009M53.09% · $1,461MUnavailable100% · $2,752M
FY 2018 Q43.39% · $123MUnavailable56.66% · $2,058M39.95% · $1,451MUnavailable100% · $3,632M
FY 2019 Q14.62% · $107MUnavailable26.78% · $620M68.6% · $1,588MUnavailable100% · $2,315M
FY 2019 Q27.43% · $128MUnavailable0.17% · $3M92.4% · $1,592MUnavailable100% · $1,723M
FY 2019 Q38.81% · $154M0% · $0M0.23% · $4M90.97% · $1,591MUnavailable100% · $1,749M
FY 2019 Q49.26% · $163M0% · $0M0.11% · $2M90.63% · $1,595MUnavailable100% · $1,760M
FY 2020 Q14.94% · $125MUnavailable25.4% · $643M69.66% · $1,763MUnavailable100% · $2,531M
FY 2020 Q29.09% · $177MUnavailable0.98% · $19M89.94% · $1,752MUnavailable100% · $1,948M
FY 2020 Q39.29% · $217M0% · $0M0.86% · $20M89.86% · $2,100MUnavailable100% · $2,337M
FY 2020 Q49.97% · $279M4.36% · $122M10.58% · $296M75.09% · $2,101MUnavailable100% · $2,798M
FY 2021 Q15.7% · $188MUnavailable23.87% · $787M70.43% · $2,322MUnavailable100% · $3,297M
FY 2021 Q27.75% · $195MUnavailable0.4% · $10M91.85% · $2,310MUnavailable100% · $2,515M
FY 2021 Q38.55% · $217M0% · $0M0.24% · $6M91.21% · $2,315MUnavailable100% · $2,538M
FY 2021 Q45.92% · $187M16.63% · $525M4.15% · $131M73.3% · $2,314MUnavailable100% · $3,157M
FY 2022 Q13.9% · $162MUnavailable35.35% · $1,470M60.75% · $2,526MUnavailable100% · $4,158M
FY 2022 Q25.38% · $143MUnavailable0.34% · $9M94.28% · $2,507MUnavailable100% · $2,659M
FY 2022 Q36.59% · $177MUnavailable0.15% · $4M93.26% · $2,504MUnavailable100% · $2,685M
FY 2022 Q47.82% · $213MUnavailable0.15% · $4M92.03% · $2,506MUnavailable100% · $2,723M
FY 2023 Q13.65% · $175M0% · $0M40.81% · $1,955M55.54% · $2,661MUnavailable100% · $4,791M
FY 2023 Q26.33% · $178M0% · $0M0.36% · $10M93.32% · $2,625MUnavailable100% · $2,813M
FY 2023 Q37.68% · $219M0% · $0M0.14% · $4M92.18% · $2,627MUnavailable100% · $2,850M
FY 2023 Q47.23% · $205MUnavailable0.11% · $3M92.66% · $2,626MUnavailable100% · $2,834M
FY 2024 Q11.43% · $193M68.2% · $9,199M9.82% · $1,324M20.55% · $2,772MUnavailable100% · $13,488M
FY 2024 Q28.03% · $241M0% · $0M0.3% · $9M91.67% · $2,750MUnavailable100% · $3,000M
FY 2024 Q32.2% · $249M73.33% · $8,294M0.15% · $17M24.32% · $2,751MUnavailable100% · $11,311M
FY 2024 Q48.56% · $291M0% · $0M10.53% · $358M80.92% · $2,752MUnavailable100% · $3,401M
FY 2025 Q15.43% · $235M4.72% · $204M22.22% · $961M67.63% · $2,925MUnavailable100% · $4,325M
FY 2025 Q28.43% · $269M0% · $0M0.38% · $12M91.19% · $2,910MUnavailable100% · $3,191M
FY 2025 Q311.56% · $381M0% · $0M0.12% · $4M88.32% · $2,911MUnavailable100% · $3,296M
FY 2025 Q410.14% · $329M0% · $0M0.09% · $3M89.76% · $2,911MUnavailable100% · $3,243M
FY 2026 Q15.48% · $265M0% · $0M30.76% · $1,489M63.76% · $3,086MUnavailable100% · $4,840M
FY 2026 Q29.47% · $322M0% · $0M0.26% · $9M90.27% · $3,070MUnavailable100% · $3,401M

Tracked cash uses · SBC excluded

Sources and calculations

Company filings · USD · Last checked 2026-10-18. Missing inputs remain unavailable. Your chart selection and layout are saved in this browser for AbbVie.

All charts share the selected dates. Quarterly/Yearly changes fiscal charts; valuation keeps completed daily closes on a published TTM basis. Later restatements can delay that basis. Historical mean, median and pricing labels use the selected range and do not estimate intrinsic fair value.

SBC deduction is an optional economic-cost scenario for FCF-based metrics. Missing SBC never becomes zero.

Revenue
Reported revenue from company filings.
Free cash flow
Operating cash flow − reported cash capital investment. PPE purchases are preferred; the productive-assets fallback also includes software and intangibles. Reflects the SBC option and can differ from issuer-defined FCF.
Net margin
Reported net income / revenue × 100.
P/E
Completed closing price × diluted shares / TTM earnings attributable to common shareholders.
ROIC
NOPAT / average invested capital × 100. NOPAT = operating income × (1 − effective tax rate). Invested capital = equity including noncontrolling interests + debt − cash and equivalents. Average uses period end and one year earlier.
Capital allocation
Reported cash uses as a percentage of tracked uses. Missing categories remain unavailable; SBC is noncash and excluded.
Reported revenue and sources